Risk Management Plans to Mitigate the Potential for Drug Shortages
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 19, 2022
May 20, 2022
bd27fc63-0c90-4718-abd5-2b5af99e540e
Related Documents
Labeling for Biosimilar and Interchangeable Biosimilar Products
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials
Guidance DocumentApril 9, 2018Center for Drug Evaluation and Research
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products
Guidance DocumentSeptember 22, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.